Julie Kim, a Korean-American, has been appointed as the new Chief Executive Officer (CEO) of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical firm. This marks the first time in Takeda's 245-year history that a woman has become CEO.

Reuters Yonhap News

Reuters Yonhap News

View original image

According to the Nihon Keizai Shimbun (Nikkei) on June 26, Kim assumed her new role as CEO of Takeda Pharmaceutical on June 24.


Kim was born in Seoul in 1970 and immigrated to the United States as a child, making her a 1.5-generation Korean American. She majored in economics at Dartmouth College and earned an MBA from the J.L. Kellogg School of Management at Northwestern University.


She built her career in the pharmaceutical industry, focusing primarily on marketing, where she was responsible for market analysis and strategic planning. She is also a former executive of Shire, an Irish pharmaceutical company that was acquired by Takeda Pharmaceutical in 2019.


At a press conference held on June 25, Kim expressed her ambition for Takeda to lead the transformation into a biopharmaceutical company utilizing artificial intelligence (AI) and advanced technologies.



As the entire pharmaceutical industry seeks to leverage AI and new technologies to reshape research and development and business structures, Kim stated her vision for positioning Takeda at the forefront of this change.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing